Literature DB >> 33381501

The Convergence of Alpha-Synuclein, Mitochondrial, and Lysosomal Pathways in Vulnerability of Midbrain Dopaminergic Neurons in Parkinson's Disease.

Georgia Minakaki1, Dimitri Krainc1, Lena F Burbulla1.   

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease, characterized by progressive bradykinesia, rigidity, resting tremor, and gait impairment, as well as a spectrum of non-motor symptoms including autonomic and cognitive dysfunction. The cardinal motor symptoms of PD stem from the loss of substantia nigra (SN) dopaminergic (DAergic) neurons, and it remains unclear why SN DAergic neurons are preferentially lost in PD. However, recent identification of several genetic PD forms suggests that mitochondrial and lysosomal dysfunctions play important roles in the degeneration of midbrain dopamine (DA) neurons. In this review, we discuss the interplay of cell-autonomous mechanisms linked to DAergic neuron vulnerability and alpha-synuclein homeostasis. Emerging studies highlight a deleterious feedback cycle, with oxidative stress, altered DA metabolism, dysfunctional lysosomes, and pathological alpha-synuclein species representing key events in the pathogenesis of PD. We also discuss the interactions of alpha-synuclein with toxic DA metabolites, as well as the biochemical links between intracellular iron, calcium, and alpha-synuclein accumulation. We suggest that targeting multiple pathways, rather than individual processes, will be important for developing disease-modifying therapies. In this context, we focus on current translational efforts specifically targeting lysosomal function, as well as oxidative stress via calcium and iron modulation. These efforts could have therapeutic benefits for the broader population of sporadic PD and related synucleinopathies.
Copyright © 2020 Minakaki, Krainc and Burbulla.

Entities:  

Keywords:  Parkinson’s disease; alpha-synuclein; calcium; dopamine; iron; mitochondria; synapse

Year:  2020        PMID: 33381501      PMCID: PMC7767856          DOI: 10.3389/fcell.2020.580634

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


  6 in total

Review 1.  An Alternative Explanation for Alzheimer's Disease and Parkinson's Disease Initiation from Specific Antibiotics, Gut Microbiota Dysbiosis and Neurotoxins.

Authors:  Kevin Roe
Journal:  Neurochem Res       Date:  2021-10-20       Impact factor: 3.996

2.  Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups.

Authors:  Karri Kaivola; Zalak Shah; Ruth Chia; Sonja W Scholz
Journal:  Brain       Date:  2022-06-03       Impact factor: 15.255

3.  Environmentally Toxic Solid Nanoparticles in Noradrenergic and Dopaminergic Nuclei and Cerebellum of Metropolitan Mexico City Children and Young Adults with Neural Quadruple Misfolded Protein Pathologies and High Exposures to Nano Particulate Matter.

Authors:  Lilian Calderón-Garcidueñas; Angélica González-Maciel; Rafael Reynoso-Robles; Héctor G Silva-Pereyra; Ricardo Torres-Jardón; Rafael Brito-Aguilar; Alberto Ayala; Elijah W Stommel; Ricardo Delgado-Chávez
Journal:  Toxics       Date:  2022-03-29

Review 4.  Synaptic Disruption by Soluble Oligomers in Patients with Alzheimer's and Parkinson's Disease.

Authors:  Berenice A Gutierrez; Agenor Limon
Journal:  Biomedicines       Date:  2022-07-19

5.  Adaptive cellular response of the substantia nigra dopaminergic neurons upon age-dependent iron accumulation.

Authors:  Kujin Kwon; Hwapyeong Cho; Soyeon Lee; Eun Jeong Cho; Weonjin Yu; Catherine Yen Li Kok; Hyunsoo Shawn Je; Jae-Ick Kim; Hyung Joon Cho; Taejoon Kwon
Journal:  Aging Cell       Date:  2022-08-19       Impact factor: 11.005

Review 6.  Does the Expression and Epigenetics of Genes Involved in Monogenic Forms of Parkinson's Disease Influence Sporadic Forms?

Authors:  Aymeric Lanore; Suzanne Lesage; Louise-Laure Mariani; Poornima Jayadev Menon; Philippe Ravassard; Helene Cheval; Olga Corti; Alexis Brice; Jean-Christophe Corvol
Journal:  Genes (Basel)       Date:  2022-03-08       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.